|cannabis||ms,spasticity in humans via survey (n=29)||Cannabis Use in People with Multiple Sclerosis and Self-Reported Spasticity||Apr 2019|
|Positive All subjects reported cannabis being somewhat or very helpful for pain and 78% (7/9) reported similar benefit for spasticity.|
|cannabis||ms,spasticity,pain in humans via placebo trial (n=30/37)||Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial||Jul 2012|
Ingestion Method: inhaled 0.8g cigarette, 4% THC |
Positive Using an objective measure, we saw a beneficial effect of inhaled cannabis on spasticity among patients receiving insufficient relief from traditional treatments. Although generally well-tolerated, smoking cannabis had acute cognitive effects.
|cannabis||ms,spasticity in humans via placebo trial (n=37/50)||Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.||Aug 2004|
Ingestion Method: oral 2.5mg THC/0.9mg CBD|
Positive A standardized Cannabis sativa plant extract might lower spasm frequency and increase mobility with tolerable side effects in MS patients with persistent spasticity not responding to other drugs.
|cannabinoids||pain,spasticity,hiv,sedative in humans via review||Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.||Jun 2015|
|Positive Most trials showed improvement in symptoms associated with cannabinoids but these associations did not reach statistical significance in all trials. Compared with placebo, cannabinoids were associated with a greater average number of patients showing a complete nausea and vomiting response (47% vs 20%; odds ratio [OR], 3.82 [95% CI, 1.55-9.42]; 3 trials), reduction in pain (37% vs 31%; OR, 1.41 [95% CI, 0.99-2.00]; 8 trials), a greater average reduction in numerical rating scale pain assessment|